DNMT3a knockout CAR T cells with Antigen Specificity (for solid tumors) (SJ-19-0024)

St. Jude Reference #SJ-19-0024

Description

Researchers at St. Jude have invented a cell therapy that consists of tumor-specific T cells in which DMNT3a is knocked out and the STAT5 pathway is activated by IL15. This is useful in developing immunotherapies for cancer and other diseases targeting defined antigens (pediatrics as well as adult). The researcher’s results indicate effector function was dramatically improved and development continues.


 

Keywords

T cell therapy, solid tumor, DMNT3 knockout, STAT5 pathway, IL15


 

Granted Patents or Published Applications


 

Related Scientific References


 

Licensing Opportunities

St. Jude is seeking a partner or partners to help develop this for use with therapies. Contact: chad.riggs@stjude.org

Related Links

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.